Enzychem Lifesciences Completes Successful Investor Roadshow in Hong Kong and Singapore
ENGLEWOOD CLIFFS, N.J., Sept. 6, 2018 /PRNewswire/ -- Enzychem Lifesciences Corporation (KOSDAQ:18930), a leading global biopharmaceutical company focusing on innovative new drug development for unmet medical needs, today announced the successful completion of a two-day investor roadshow in Singapore and Hong Kong from September 4 to 5, 2018, with leading financial institutions and retail brokers in the Asia-Pacific region.
As one of the fastest growing life science companies by market capitalization on Korea Securities Dealer Automated Quotation (KOSDAQ), the investor meetings were hosted by the Korean Stock Exchange and provided a select group of promising biopharmaceutical companies listed on the KOSDAQ Stock Exchange an opportunity to meet with institutional investors in Singapore and Hong Kong. During two-day event, Enzychem had chance to meet with multiple financial institutions including Whitefield Capital, Oaktree Capital, NH Investment, Nikko Asset Management, Baring Asset, UBP Asset and many others. The meetings gave potential investors an update on the status of Enzychem's R&D activities, with a particular focus on lead product candidate, EC-18, as well as new corporate developments.
"Given the clinical advancement of our lead product EC-18 in multiple indications, we are in the process of moving towards becoming a late-stage biopharmaceutical company," said Chairman & CEO Ki Young Sohn of Enzychem Lifesciences. "A number of productive investor meetings were conducted over this two day period, and we are delighted with both the turnout and interest to learn more about our clinical pipeline and strategic activities," he added.
Enzychem Lifesciences is a Korea-based biopharmaceutical company dedicated to developing innovative new drugs with unmet clinical need. The company's lead compound, EC 18, is an immune modulator in clinical trials in the U.S. for three different indications including Chemotherapy Induced Neutropenia (CIN), Chemoradiation Induced Oral Mucositis (CRIOM), and Acute Radiation Syndrome (ARS). The Company was awarded Fast Track Status for EC-18 in CRIOM and Orphan Drug Designation in ARS. CIN and CRIOM are in Phase II clinical trials and ARS is in process to start Phase II clinical studies.
About Enzychem Lifesciences Corporation
Enzychem Lifesciences, Corp. (KOSDAQ:183490) is a global biopharmaceutical company headquartered in Seoul, Korea, which is dedicated to developing new drugs and APIs (Active Pharmaceutical Ingredients). Since its foundation in 1999, Enzychem Lifesciences has been striving to develop new and innovative treatments capable of addressing unmet medical needs with R&D-driven approaches under its grand mission of "Saving Human Lives by Overcoming Unmet Medical Needs"
EC-18, the lead compound of Enzychem Lifesciences, is an immune modulator driven from deer antler that has the potential to be used for a variety of indications. At present, three clinical trials for different indications are being conducted; Chemotherapy Induced Neutropenia (CIN), Chemoradiation Induced Oral Mucositis (CRIOM), and Acute Radiation Syndrome (ARS). In order to facilitate the clinical trial process, Enzychem launched a US operation in New Jersey.
Currently, Enzychem Lifesciences is one of the fastest growing life science companies in KOSDAQ Stock Exchange in terms of market capitalization. The company is headquartered in Seoul, Korea.
For more information on Enzychem Lifesciences, visit http://www.enzychem.com/
View original content with multimedia:http://www.prnewswire.com/news-releases/enzychem-lifesciences-completes-successful-investor-roadshow-in-hong-kong-and-singapore-300708326.html
SOURCE Enzychem Lifesciences Corporation
